EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A

Robert F Sidonio, Eric S Mullins, Flora Peyvandi, Anthony K C Chan, Oleksandra Stasyshyn, Seoh Leng Yeoh, Darintr Sosothikul, Ali Bulent Antmen, Samer S El-Kamary, Joan Gu, Srilatha Tangada

Research and Practice in Thrombosis and Haemostasis · 2026-08 · 10 (6) · 106939

DOI: 10.1016/j.rpth.2026.106939 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026-08. Verfasst von Robert F Sidonio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Hemorrhage, Polyethylene Glycols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In severe hemophilia A, factor VIII (FVIII) replacement is essential, but FVIII inhibitor development can be serious.

Objectives

This phase 3, prospective, uncontrolled, open-label, multicenter study (NCT02615691) investigated the immunogenicity, efficacy, and safety of rurioctocog alfa pegol for severe hemophilia A in previously untreated patients.

Methods

Patients received intravenous prophylaxis (25-50 IU/kg, up to 80 IU/kg, ≥1 dose weekly) and/or on-demand therapy (10-50 IU/kg, up to 80 IU/kg depending on bleed severity). The primary endpoint was FVIII inhibitor incidence (≥0.6 BU/mL [Nijmegen modification of Bethesda assay]) in the full analysis set (patients with ≥100 exposure-days [EDs] or who developed an inhibitor). We present the final data.

Results

Of 146 enrolled patients, 120 received ≥1 dose; all were male, and 55.8% had a family history of hemophilia A. Median (range) age was 9.6 (1.2-60.0) months. In the full analysis set (N = 100), 11 patients developed FVIII inhibitors, and 89 had ≥100 EDs without developing inhibitors (incidence [95% CI], 0.110 [0.056-0.188]). In post hoc analyses, 11 patients developed inhibitors, and 101 and 96 had ≥20 and ≥50 EDs, respectively, without developing inhibitors (incidence [95% CI], 0.098 [0.050-0.169] and 0.103 [0.052-0.177], respectively). Annualized bleeding rates (95% CI) were 1.7 (1.2-2.4), 1.0 (0.7-1.3), and 2.3 (1.7-3.2) for once-weekly prophylaxis, >1× weekly prophylaxis, and on-demand therapy, respectively. Overall, 109 of 120 (90.8%) patients had 745 adverse events; serious adverse events occurred in 47 (39.2%) patients.

Conclusion

These data demonstrate a low incidence of FVIII inhibitors among previously untreated patients receiving rurioctocog alfa pegol for severe hemophilia A. Efficacy and safety results were similar to prior reports in previously treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHemorrhagePolyethylene GlycolsCoagulantsHumansMaleProspective StudiesChild, PreschoolInfantTreatment OutcomeChildSeverity of Illness Index

Stichwörter der Autor:innen

antibodieschildfactor VIIIhemophilia Aneutralizingprospective studies

Substanzen

Factor VIIIBAX 855Polyethylene GlycolsCoagulants

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA.
  • Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia, Milan, Italy.
  • Thrombosis Centre and Fondazione Luigi Villa, Milan, Italy.
  • McMaster Children's Hospital, Hamilton, Ontario, Canada.
  • Academy of Medical Sciences of Ukraine, Lviv, Ukraine.

Förderung

  • Takeda Development Center Americas

Zitieren

APA

Sidonio, R. F., Mullins, E. S., Peyvandi, F., Chan, A. K. C., Stasyshyn, O., Yeoh, S. L., Sosothikul, D., Antmen, A. B., El-Kamary, S. S., Gu, J., & Tangada, S. (2026). Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 10(6), 106939. https://doi.org/10.1016/j.rpth.2026.106939

Vancouver

Sidonio RF, Mullins ES, Peyvandi F, Chan AKC, Stasyshyn O, Yeoh SL, et al. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis. 2026;10(6):106939. doi:10.1016/j.rpth.2026.106939

BibTeX
@article{Sidonio2026,
  author = {Sidonio, Robert F and Mullins, Eric S and Peyvandi, Flora and Chan, Anthony K C and Stasyshyn, Oleksandra and Yeoh, Seoh Leng and Sosothikul, Darintr and Antmen, Ali Bulent and El-Kamary, Samer S and Gu, Joan and Tangada, Srilatha},
  title = {Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {106939},
  doi = {10.1016/j.rpth.2026.106939}
}
Kostenlos starten →